Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany.
Institute of Pathology, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Cell Physiol Biochem. 2021 Dec 23;55(S4):96-112. doi: 10.33594/000000476.
BACKGROUND/AIMS: The number of patients of older age with metabolic syndrome, obesity, and associated kidney disease, which is characterized by podocyte damage, glomerular hypertrophy, and focal segmental glomerulosclerosis (FSGS), is increasing worldwide. Animal models that would reflect the development of such kidney diseases could facilitate the testing of drugs. We investigated the renal effects of a long-term high caloric diet in aged rats and the potential effects of drugs used to treat metabolic syndrome.
We analyzed nine-month-old male and female Sprague Dawley rats fed five months with a normal diet (control group) or high-fat-high-carbohydrate diet (HFHCD group). Two additional groups were fed with HFHCD and treated with drugs used in patients with metabolic syndrome, i.e., the glucagon-like peptide receptor 1 agonist liraglutide (HFHCD+liraglutide group) or metformin (HFHCD+metformin group).
Except an increase of waist circumference as a sign of visceral obesity, the HFHCD diet did not induce metabolic syndrome or obesity. There were no significant changes in kidney function and all groups showed similar indices of glomerular injury, i.e., no differences in glomerular size or the number of glomeruli with FSGS or with FSGS-precursor lesions quantified by CD44 expression as a marker of parietal epithelial cell (PEC) activation. Analysis of ultrastructural morphology revealed mild podocyte stress and a decrease of glomerular nestin expression in the HFHCD group, whereas podocin and desmin were not altered. HFHCD did not promote fibrogenesis, however, treatment with liraglutide led to a slightly increased tubulointerstitial damage, immune cell infiltration, and collagen IV expression compared to the control and HFHCD groups.
A five-month feeding with HFHCD in aged rats induced mild podocyte injury and microinflammation, which was not alleviated by liraglutide or metformin.
背景/目的:随着代谢综合征、肥胖症以及与年龄相关的肾脏疾病患者人数的增加,这些患者的特征是足细胞损伤、肾小球肥大和局灶节段性肾小球硬化症(FSGS),全世界范围内对反映此类肾脏疾病发展的动物模型的需求也在不断增加。此类动物模型可促进对治疗代谢综合征药物的测试。我们研究了长期高卡路里饮食对老年大鼠肾脏的影响,以及用于治疗代谢综合征的药物的潜在影响。
我们分析了 9 个月大的雄性和雌性 Sprague Dawley 大鼠,它们在 5 个月内分别喂食正常饮食(对照组)或高脂肪高碳水化合物饮食(HFHCD 组)。另外两组大鼠喂食 HFHCD 并接受代谢综合征患者所用药物治疗,即胰高血糖素样肽-1 受体激动剂利拉鲁肽(HFHCD+利拉鲁肽组)或二甲双胍(HFHCD+二甲双胍组)。
除了腰围增加作为内脏肥胖的标志外,HFHCD 饮食并未诱导代谢综合征或肥胖症。肾功能无明显变化,所有组的肾小球损伤指数相似,即肾小球大小或 FSGS 肾小球数量无差异,FSGS 前体病变通过 CD44 表达作为壁细胞(PEC)激活的标志物进行定量也无差异。超微结构形态学分析显示 HFHCD 组轻度足细胞应激和肾小球巢蛋白表达减少,而足蛋白和结蛋白未改变。HFHCD 并未促进纤维化,然而,与对照组和 HFHCD 组相比,利拉鲁肽治疗导致肾小管间质损伤、免疫细胞浸润和胶原 IV 表达略有增加。
在老年大鼠中进行 5 个月的 HFHCD 喂养会导致轻度的足细胞损伤和微炎症,而利拉鲁肽或二甲双胍并不能缓解这种损伤和炎症。